All In Biotech

Drug Trial Radar · NCT05248880

A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines

A Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of AGN-151586 for the Treatment of Glabellar Lines in Toxin-Naïve Subjects

Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 309 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

309

Actual

Start

Mar 8, 2022

Primary completion

Feb 1, 2023

Study completion Feb 1, 2023

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Feb 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. AGN-151586 is an investigational product being developed for the treatment of GL. The purpose of this study is to evaluate the safety and efficacy of AGN-151586 for the treatment of GL in toxin-naïve participants with moderate to severe GL. This is a 12 week study in which eligible subjects will be enrolled into the study containing 2 treatment periods, double-blind period and open-label period. Participants are randomly assigned to receive AGN-151586 or placebo. There is 1 in a 4 chance that participants will receive placebo. Around 300 adult participants with moderate to severe GL will be enrolled in the study in approximately 15 sites. Participants will receive either AGN-151586 or Placebo administered as 5 intramuscular injections to the glabellar complex on Day 1. Participants meeting retreatment criteria may receive an open-label treatment of AGN-151586 during the study. Participants will attend regular visits during the study at a study site. The effect of the treatment will be checked by medical assessments, blood tests, telephone calls, questionnaires and checking for side effects.

Conditions

  • Glabellar Lines

Interventions

  • AGN-151586Drug

    Intramuscular Injection

  • PlaceboDrug

    Intramuscular Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [US FDA]Time frame: Baseline, Day 7 (Double-blind period)
  2. Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]Time frame: Baseline, Day 7 (Double-blind period)
  3. Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]Time frame: Baseline, Day 7 (Double-blind Period)
  4. Number of Participants With Adverse EventsTime frame: From time of informed consent to end of study; median time on follow-up was 85 days for all groups.

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Clear Dermatology & Aesthetics Center /ID# 238990

    Scottsdale, Arizona

  • Steve Yoelin MD Medical Associate Inc /ID# 243197

    Newport Beach, California

  • Marcus Medical Spa /ID# 241703

    Redondo Beach, California

  • DMR Research PLLC /ID# 239061

    Westport, Connecticut

  • Duplicate_Kavali Plastic Surgery and Skin Renewal Center /ID# 244808

    Atlanta, Georgia

  • DelRicht Research /ID# 244890

    Baton Rouge, Louisiana

  • Maryland Dermatology Laser, Skin, & Vein Institute /ID# 239067

    Hunt Valley, Maryland

  • WDC Cosmetic and Research, PLLC /ID# 233935

    Wilmington, North Carolina

  • Clinical Research Center of the Carolinas /ID# 239064

    Charleston, South Carolina

  • Duplicate_Austin Institute for Clinical Research /ID# 238989

    Pflugerville, Texas

  • Kalo Clinical Research /ID# 247279

    West Valley City, Utah

  • SkinDC /ID# 238988

    Arlington, Virginia

  • YVR Aesthetics Training & Study Centre /ID# 241858

    Vancouver, British Columbia, Canada

  • Pacific Derm /ID# 239654

    Vancouver, British Columbia, Canada

  • Dr Melinda Gooderham Medicine Profession /ID# 239657

    Cobourg, Ontario, Canada

  • The Centre for Clinical Trials /ID# 245873

    Oakville, Ontario, Canada

  • Clinique D /ID# 239653

    Laval, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.